Serious adverse events
|
BGF MDI 320/14.4/9.6 μg |
BGF MDI 160/14.4/9.6 μg |
GFF MDI 14.4/9.6 μg |
BFF MDI 320/9.6 μg |
Total subjects affected by serious adverse events
|
|
|
|
|
subjects affected / exposed
|
426 / 2144 (19.87%) |
445 / 2124 (20.95%) |
433 / 2125 (20.38%) |
440 / 2136 (20.60%) |
number of deaths (all causes)
|
27 |
42 |
47 |
35 |
number of deaths resulting from adverse events
|
20 |
28 |
35 |
29 |
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
|
|
|
|
|
Lung neoplasm malignant
|
|
|
|
|
subjects affected / exposed
|
4 / 2144 (0.19%) |
5 / 2124 (0.24%) |
2 / 2125 (0.09%) |
4 / 2136 (0.19%) |
occurrences causally related to treatment / all
|
0 / 4 |
0 / 5 |
0 / 2 |
0 / 4 |
deaths causally related to treatment / all
|
0 / 0 |
1 / 1 |
1 / 1 |
1 / 1 |
Prostate cancer
|
|
|
|
|
subjects affected / exposed
|
3 / 2144 (0.14%) |
1 / 2124 (0.05%) |
2 / 2125 (0.09%) |
3 / 2136 (0.14%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 1 |
0 / 2 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Lung adenocarcinoma
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
1 / 2124 (0.05%) |
4 / 2125 (0.19%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 4 |
0 / 12 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Non-small cell lung cancer
|
|
|
|
|
subjects affected / exposed
|
2 / 2144 (0.09%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
2 / 2136 (0.09%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Transitional cell carcinoma
|
|
|
|
|
subjects affected / exposed
|
2 / 2144 (0.09%) |
2 / 2124 (0.09%) |
0 / 2125 (0.00%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 2 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Metastases to liver
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
1 / 2124 (0.05%) |
1 / 2125 (0.05%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Oesophageal carcinoma
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
0 / 2124 (0.00%) |
2 / 2125 (0.09%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 2 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Squamous cell carcinoma of lung
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
1 / 2124 (0.05%) |
1 / 2125 (0.05%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Breast cancer
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
2 / 2136 (0.09%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Pancreatic carcinoma
|
|
|
|
|
subjects affected / exposed
|
2 / 2144 (0.09%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Pancreatic carcinoma metastatic
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
2 / 2125 (0.09%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 2 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
1 / 1 |
1 / 1 |
Small cell lung caner
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
1 / 2125 (0.05%) |
2 / 2136 (0.09%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Adenocarcinoma
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
1 / 2125 (0.05%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Basal cell carcinoma
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Benign lung neoplasm
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Bronchial carcinoma
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Colorectal cancer
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Malignant palate neoplasm
|
|
|
|
|
subjects affected / exposed
|
2 / 2144 (0.09%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Metastases to central nervous system
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Metastases to lung
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
2 / 2125 (0.09%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Oesophageal squamous cell carcinoma
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
1 / 2125 (0.05%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Squamous cell carcinoma
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
2 / 2124 (0.09%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Abdominal wall neoplasm
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Acute myeloid leukaemia
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Adenocarcinoma gastric
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Adenocarcinoma of colon
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Adenocarcinoma pancreas
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Adenosquamous cell lung cancer
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Bladder cancer
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Breast cancer in situ
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Breast cancer stage IV
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Colon cancer metastatic
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Colon neopplasm
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
1 / 2125 (0.05%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Diffuse large B-cell lymphoma
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Gastric cancer
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Gastrointestinal lymphoma
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
1 / 2125 (0.05%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Gastrooesophageal cancer
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Glioblastoma
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
1 / 2125 (0.05%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Hepatic cancer metastatic
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Hepatocellular carcinoma
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Invasive breast carcinoma
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Invasive ductal breast carcinoma
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Laryngeal cancer
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Laryngeal squamous cell carcinoma
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
1 / 2125 (0.05%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Metasteses to bone
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Metastases to nervous system
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
1 / 2125 (0.05%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Metastatic bronchial carcinoma
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Oesophageal cancer metastatic
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
1 / 2125 (0.05%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Oropharyngeal squamous cell carcinoma
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Papillary renal cell carcinoma
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Rectal adenocarcinoma
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Recosigmoid cancer
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Renal cancer
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
1 / 2125 (0.05%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Renal cell carcinoma
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Renal neoplasm
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
1 / 2125 (0.05%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Tonsil cancer
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Non-Hodgkins lymphoma
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
1 / 2125 (0.05%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Rectal cancer
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Lung neoplasm
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Vascular disorders
|
|
|
|
|
Hypertension
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
2 / 2124 (0.09%) |
3 / 2125 (0.14%) |
2 / 2136 (0.09%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
0 / 3 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Peripheral arterial occlusive disease
|
|
|
|
|
subjects affected / exposed
|
3 / 2144 (0.14%) |
3 / 2124 (0.14%) |
0 / 2125 (0.00%) |
2 / 2136 (0.09%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 3 |
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Deep vein thrombosis
|
|
|
|
|
subjects affected / exposed
|
4 / 2144 (0.19%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 4 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Hypertensive crisis
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
2 / 2124 (0.09%) |
0 / 2125 (0.00%) |
2 / 2136 (0.09%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Aortic aneurysm
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
3 / 2125 (0.14%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 3 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Hypotension
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
2 / 2124 (0.09%) |
1 / 2125 (0.05%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Aortic dissection
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Arteriosclerosis
|
|
|
|
|
subjects affected / exposed
|
2 / 2144 (0.09%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
2 / 2 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Circulatory collapse
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
1 / 2125 (0.05%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Hypertensive urgency
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
1 / 2125 (0.05%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Iliac artery occlusion
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Peripheral Ischaemia
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Peripheral vascular disorder
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
1 / 2125 (0.05%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Accelerated hypertension
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Aortic arteriosclerosis
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Aortic stenosis
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
1 / 2125 (0.05%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Haematoma
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Peripheral artery occlusion
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Peripheral artery stenosis
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Shock Haemorrhagic
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Subclavian artery stenosis
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Thrombophlebitis
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
General disorders and administration site conditions
|
|
|
|
|
Death
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
4 / 2124 (0.19%) |
7 / 2125 (0.33%) |
2 / 2136 (0.09%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 4 |
1 / 7 |
0 / 2 |
deaths causally related to treatment / all
|
1 / 1 |
4 / 4 |
7 / 7 |
2 / 2 |
Chest pain
|
|
|
|
|
subjects affected / exposed
|
3 / 2144 (0.14%) |
4 / 2124 (0.19%) |
2 / 2125 (0.09%) |
2 / 2136 (0.09%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 4 |
0 / 2 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Multiple organ dysfunction syndrome
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
1 / 1 |
0 / 0 |
1 / 1 |
Sudden death
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
1 / 1 |
1 / 1 |
0 / 0 |
1 / 1 |
Drug withdrawal syndrome
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Oedema peripheral
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Asthenia
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Capsular contracture associated with breast implant
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Fatigue
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
1 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Pain
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Soft tissue inflamation
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Sudden cardiac death
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
1 / 2125 (0.05%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Systemic inflammatory response syndrome
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Non-cardiac chest pain
|
|
|
|
|
subjects affected / exposed
|
4 / 2144 (0.19%) |
1 / 2124 (0.05%) |
2 / 2125 (0.09%) |
4 / 2136 (0.19%) |
occurrences causally related to treatment / all
|
0 / 4 |
0 / 1 |
0 / 2 |
0 / 4 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Immune system disorders
|
|
|
|
|
Drug hypersensitivity
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Anaphylactic reaction
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
2 / 2124 (0.09%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Allergy to arthropod sting
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Type I hypersensitivity
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Reproductive system and breast disorders
|
|
|
|
|
Benign prostatic hyperplasia
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Endometrial hyperplasia
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Ovarian Cyst
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
1 / 2125 (0.05%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Scrotal cyst
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
1 / 2125 (0.05%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Vaginal leukoplakia
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Respiratory, thoracic and mediastinal disorders
|
|
|
|
|
Chronic obstructive pulmonary disease
|
|
|
|
|
subjects affected / exposed
|
202 / 2144 (9.42%) |
221 / 2124 (10.40%) |
219 / 2125 (10.31%) |
241 / 2136 (11.28%) |
occurrences causally related to treatment / all
|
16 / 255 |
21 / 263 |
12 / 268 |
17 / 299 |
deaths causally related to treatment / all
|
3 / 3 |
3 / 3 |
2 / 2 |
4 / 4 |
Acute respiratory failure
|
|
|
|
|
subjects affected / exposed
|
14 / 2144 (0.65%) |
20 / 2124 (0.94%) |
20 / 2125 (0.94%) |
7 / 2136 (0.33%) |
occurrences causally related to treatment / all
|
0 / 16 |
0 / 20 |
1 / 20 |
0 / 7 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Respiratory failure
|
|
|
|
|
subjects affected / exposed
|
10 / 2144 (0.47%) |
9 / 2124 (0.42%) |
5 / 2125 (0.24%) |
9 / 2136 (0.42%) |
occurrences causally related to treatment / all
|
0 / 10 |
0 / 9 |
0 / 5 |
1 / 9 |
deaths causally related to treatment / all
|
2 / 2 |
2 / 2 |
0 / 0 |
3 / 3 |
Pulmonary emboism
|
|
|
|
|
subjects affected / exposed
|
4 / 2144 (0.19%) |
3 / 2124 (0.14%) |
5 / 2125 (0.24%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
1 / 4 |
0 / 3 |
0 / 5 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Pneumothorax
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
3 / 2124 (0.14%) |
3 / 2125 (0.14%) |
4 / 2136 (0.19%) |
occurrences causally related to treatment / all
|
0 / 0 |
1 / 3 |
0 / 3 |
0 / 6 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Dyspnoea
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
2 / 2124 (0.09%) |
4 / 2125 (0.19%) |
2 / 2136 (0.09%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
0 / 4 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Hypoxia
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
1 / 2124 (0.05%) |
1 / 2125 (0.05%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Haemoptysis
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
3 / 2124 (0.14%) |
0 / 2125 (0.00%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 0 |
1 / 3 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Pulmonary mass
|
|
|
|
|
subjects affected / exposed
|
3 / 2144 (0.14%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Acute pulmonary oedema
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
0 / 2124 (0.00%) |
1 / 2125 (0.05%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Chronic respiratory failure
|
|
|
|
|
subjects affected / exposed
|
2 / 2144 (0.09%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Pleural effusion
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Pleurisy
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
2 / 2136 (0.09%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Respiratory distress
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
2 / 2125 (0.09%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Acute respiratory distress syndrome
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
1 / 2125 (0.05%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Laryngeal polyp
|
|
|
|
|
subjects affected / exposed
|
2 / 2144 (0.09%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Organising pneumonia
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Respiratory arrest
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
2 / 2136 (0.09%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Sleep apnoea syndrome
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
0 / 2124 (0.00%) |
1 / 2125 (0.05%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Vocal cord leukoplakia
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Bronchial secretion retention
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Bronchospasm
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Cystic lung disease
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Haemothorax
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
1 / 2125 (0.05%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Hypercapnia
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Nasal congestion
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Nasal polyps
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Nasal turbinate hypertrophy
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Pleurtitic pain
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Pulmonary calcification
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Pulmonary fibrosis
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Pnuemonia aspiration
|
|
|
|
|
subjects affected / exposed
|
2 / 2144 (0.09%) |
2 / 2124 (0.09%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 2 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Psychiatric disorders
|
|
|
|
|
Alcohol withdrawal syndrome
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
1 / 2125 (0.05%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Schizoaffective disorder
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
0 / 2124 (0.00%) |
1 / 2125 (0.05%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Suicidal ideation
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Suicicide attempt
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
1 / 2125 (0.05%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Affective disorder
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Alcoholism
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
1 / 2125 (0.05%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Hallucination
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Persistent depressive disorder
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
1 / 2125 (0.05%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Investigations
|
|
|
|
|
Troponin increased
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Blood folate decreased
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Blood magnesium decreased
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
1 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Electrocradiogram ST-T change
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Electrocardiogram abnormal
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
1 / 2125 (0.05%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Oxygen saturation decreased
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
1 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Prothrombin time abnormal
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Injury, poisoning and procedural complications
|
|
|
|
|
Hip fracture
|
|
|
|
|
subjects affected / exposed
|
4 / 2144 (0.19%) |
3 / 2124 (0.14%) |
1 / 2125 (0.05%) |
5 / 2136 (0.23%) |
occurrences causally related to treatment / all
|
0 / 4 |
0 / 3 |
0 / 1 |
1 / 5 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Ankle fracture
|
|
|
|
|
subjects affected / exposed
|
3 / 2144 (0.14%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
3 / 2136 (0.14%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 0 |
0 / 0 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Fall
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
2 / 2124 (0.09%) |
2 / 2125 (0.09%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 1 |
1 / 2 |
0 / 2 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Femoral neck fracture
|
|
|
|
|
subjects affected / exposed
|
2 / 2144 (0.09%) |
2 / 2124 (0.09%) |
0 / 2125 (0.00%) |
2 / 2136 (0.09%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 2 |
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Femur fracture
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
1 / 2124 (0.05%) |
2 / 2125 (0.09%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 2 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Lower limb fracture
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
1 / 2124 (0.05%) |
1 / 2125 (0.05%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Radius fracture
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
2 / 2124 (0.09%) |
1 / 2125 (0.05%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Meniscus injury
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
2 / 2124 (0.09%) |
1 / 2125 (0.05%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Road traffic accident
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Spinal compression fracture
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
1 / 2124 (0.05%) |
1 / 2125 (0.05%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Abdominal wound dehiscene
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
1 / 2125 (0.05%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Foot fracture
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Lumbar vertebral fracture
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
0 / 2124 (0.00%) |
1 / 2125 (0.05%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Multiple injuries
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Post procedural hemorrhage
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
2 / 2124 (0.09%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Thoracic vertebral fracture
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Tibia fracture
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
2 / 2136 (0.09%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Ulna fracture
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
1 / 2125 (0.05%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Accidental overdose
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Concussion
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
1 / 2125 (0.05%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Epicondylitis
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Foreign body aspiration
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
1 / 2125 (0.05%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Foreign body in gastrointestinal tract
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Hand Fracture
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
1 / 2125 (0.05%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Humerous fracture
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Jaw fracture
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Joint dislocation
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Limb traumatic amputation
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Multiple fractures
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Ocular procedural complication
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Pelvic fracture
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Procedural pneumothorax
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Pubis fracture
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Radiation proctitis
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Sternal fracture
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Subdural hematoma
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Tendon rupture
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Upper limb fracture
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
1 / 2125 (0.05%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Venomous bite
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Wound decomposition
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Wound dehiscence
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
1 / 2125 (0.05%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Wrist fracture
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Rib fracture
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
1 / 2124 (0.05%) |
1 / 2125 (0.05%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Contussion
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
1 / 2125 (0.05%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Penetrating abdominal trauma
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Pneumoconiosis
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Spinal fracture
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
1 / 2125 (0.05%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Thermal burn
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
1 / 2125 (0.05%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Toxicity to various agents
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Wound evisceration
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
1 / 2125 (0.05%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Cardiac disorders
|
|
|
|
|
Acute myocardial infarction
|
|
|
|
|
subjects affected / exposed
|
7 / 2144 (0.33%) |
10 / 2124 (0.47%) |
17 / 2125 (0.80%) |
7 / 2136 (0.33%) |
occurrences causally related to treatment / all
|
0 / 8 |
0 / 10 |
2 / 18 |
0 / 7 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
2 / 2 |
0 / 0 |
Atrial fibrilation
|
|
|
|
|
subjects affected / exposed
|
9 / 2144 (0.42%) |
8 / 2124 (0.38%) |
14 / 2125 (0.66%) |
3 / 2136 (0.14%) |
occurrences causally related to treatment / all
|
0 / 9 |
3 / 8 |
0 / 15 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Myocardial infarction
|
|
|
|
|
subjects affected / exposed
|
5 / 2144 (0.23%) |
5 / 2124 (0.24%) |
7 / 2125 (0.33%) |
4 / 2136 (0.19%) |
occurrences causally related to treatment / all
|
0 / 5 |
1 / 5 |
0 / 7 |
0 / 4 |
deaths causally related to treatment / all
|
1 / 1 |
1 / 1 |
3 / 3 |
1 / 1 |
Coronary artery disease
|
|
|
|
|
subjects affected / exposed
|
5 / 2144 (0.23%) |
5 / 2124 (0.24%) |
7 / 2125 (0.33%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 5 |
0 / 5 |
0 / 7 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Cardiac failure congestive
|
|
|
|
|
subjects affected / exposed
|
5 / 2144 (0.23%) |
3 / 2124 (0.14%) |
5 / 2125 (0.24%) |
2 / 2136 (0.09%) |
occurrences causally related to treatment / all
|
0 / 6 |
0 / 3 |
1 / 6 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Cardiac arrest
|
|
|
|
|
subjects affected / exposed
|
3 / 2144 (0.14%) |
1 / 2124 (0.05%) |
8 / 2125 (0.38%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
1 / 3 |
0 / 1 |
1 / 8 |
0 / 0 |
deaths causally related to treatment / all
|
3 / 3 |
0 / 0 |
7 / 7 |
0 / 0 |
Angina pectoris
|
|
|
|
|
subjects affected / exposed
|
3 / 2144 (0.14%) |
0 / 2124 (0.00%) |
3 / 2125 (0.14%) |
5 / 2136 (0.23%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 0 |
0 / 3 |
1 / 5 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Cardiac failure
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
3 / 2124 (0.14%) |
2 / 2125 (0.09%) |
3 / 2136 (0.14%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 3 |
0 / 2 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Angina unstable
|
|
|
|
|
subjects affected / exposed
|
3 / 2144 (0.14%) |
1 / 2124 (0.05%) |
3 / 2125 (0.14%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 1 |
0 / 3 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Cardiac failure acute
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
1 / 2124 (0.05%) |
4 / 2125 (0.19%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 4 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
1 / 1 |
1 / 1 |
0 / 0 |
Cardiorespiratory arrest
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
4 / 2125 (0.19%) |
2 / 2136 (0.09%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 4 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
1 / 1 |
3 / 3 |
2 / 2 |
Acute coronary syndrome
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
3 / 2124 (0.14%) |
1 / 2125 (0.05%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
1 / 1 |
0 / 3 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Stress cardiomyopathy
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
3 / 2124 (0.14%) |
1 / 2125 (0.05%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 3 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Arteriosclerosis coronary artery
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
1 / 2125 (0.05%) |
2 / 2136 (0.09%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Atrial flutter
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
2 / 2124 (0.09%) |
0 / 2125 (0.00%) |
2 / 2136 (0.09%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
0 / 0 |
1 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Supraventricular tachycardia
|
|
|
|
|
subjects affected / exposed
|
2 / 2144 (0.09%) |
1 / 2124 (0.05%) |
1 / 2125 (0.05%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Arrhythmia
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
1 / 2124 (0.05%) |
1 / 2125 (0.05%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Bradycardia
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
2 / 2124 (0.09%) |
1 / 2125 (0.05%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Acute left ventricular failure
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
1 / 2125 (0.05%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Atrioventricular block complete
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
0 / 2124 (0.00%) |
1 / 2125 (0.05%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Coronary artery occulsion
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Myocardial ischaemia
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
1 / 2125 (0.05%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Pulseless electrical activity
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
1 / 2125 (0.05%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Ventricular fibrillation
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
1 / 2125 (0.05%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Atriventricular block second degree
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
1 / 2125 (0.05%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Cardiac disorder
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Cardio-respiratory distress
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Cardiac failure chronic
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
1 / 2125 (0.05%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Cardiogenic shock
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
1 / 2125 (0.05%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Cardiovascular disorder
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
1 / 2125 (0.05%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Cardiovascular insufficency
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Coronary artery stenosis
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
1 / 2125 (0.05%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Hypertensive heart disease
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Ischaemic cardiomyopathy
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Left ventricular failure
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Mitral valve incompetence
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Myocarditis
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Sinus node dysfunction
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Tachycardia
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
1 / 2125 (0.05%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Tricuspid valve incompetence
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Trifascicular black
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
1 / 2125 (0.05%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Ventricular tachycardia
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
1 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Cor pulmonale
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Right ventricular failure
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
1 / 2125 (0.05%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Nervous system disorders
|
|
|
|
|
Cerebrovascular accident
|
|
|
|
|
subjects affected / exposed
|
8 / 2144 (0.37%) |
2 / 2124 (0.09%) |
4 / 2125 (0.19%) |
3 / 2136 (0.14%) |
occurrences causally related to treatment / all
|
0 / 8 |
0 / 3 |
0 / 4 |
0 / 3 |
deaths causally related to treatment / all
|
1 / 1 |
0 / 0 |
1 / 1 |
0 / 0 |
Syncope
|
|
|
|
|
subjects affected / exposed
|
2 / 2144 (0.09%) |
3 / 2124 (0.14%) |
1 / 2125 (0.05%) |
4 / 2136 (0.19%) |
occurrences causally related to treatment / all
|
0 / 2 |
1 / 3 |
0 / 1 |
0 / 4 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Cerebral infarction
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
5 / 2136 (0.23%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
1 / 5 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Carotid artery stenosis
|
|
|
|
|
subjects affected / exposed
|
2 / 2144 (0.09%) |
2 / 2124 (0.09%) |
0 / 2125 (0.00%) |
2 / 2136 (0.09%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 2 |
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Siezure
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
4 / 2124 (0.19%) |
1 / 2125 (0.05%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
1 / 4 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Encephalopathy
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
2 / 2136 (0.09%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Cerebellar infarction
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
1 / 2124 (0.05%) |
1 / 2125 (0.05%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Dizziness
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
0 / 2124 (0.00%) |
1 / 2125 (0.05%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Subarachnoid haemorrhage
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
0 / 2124 (0.00%) |
1 / 2125 (0.05%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Ataxia
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
2 / 2125 (0.09%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Cerebral ischaemia
|
|
|
|
|
subjects affected / exposed
|
2 / 2144 (0.09%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Intracranial aneurysm
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
1 / 2125 (0.05%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Ischaemic stroke
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
2 / 2125 (0.09%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Aphasia
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Brain injury
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
1 / 2125 (0.05%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Carpal tunnel syndrome
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Cerebral haemorrhage
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Cerebrospinal fluid leakage
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Cervical radiculopathy
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Colloid brain cyst
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Embolic Cerebral infarction
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Epilepsy
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
1 / 2125 (0.05%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Guillain-Barre syndrome
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Haemorrhage intercranial
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Hemorrhagic stroke
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Headache
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Hemiparesis
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Hyopercapnic coma
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
1 / 2125 (0.05%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Intercostal neuralgia
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Lacunar infarction
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
1 / 2125 (0.05%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Loss of consciousness
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Lumbar radiculopathy
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Monparesis
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Myelopathy
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Ruptured cerebral aneurysm
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Sciatica
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Spinal claudication
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Vocal cord paralysis
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Transient ischaemic attack
|
|
|
|
|
subjects affected / exposed
|
3 / 2144 (0.14%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Generalised tonic-clonic seizure
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Blood and lymphatic system disorders
|
|
|
|
|
Anaemia
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
2 / 2124 (0.09%) |
0 / 2125 (0.00%) |
2 / 2136 (0.09%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Iron deficiancy anaemia
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Anaemia macrocytic
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Immune thrombocytopenic purpura
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Lymphadenopathy
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Neutropenia
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Thrombocytopenia
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Ear and labyrinth disorders
|
|
|
|
|
Vertigo
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
2 / 2124 (0.09%) |
1 / 2125 (0.05%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 0 |
1 / 2 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Eye disorders
|
|
|
|
|
Cataract
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Retinal detachment
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Eyelid ptosis
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Retinal vascular thrombosis
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Visual impairment
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
1 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Retinal degeneration
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Gastrointestinal disorders
|
|
|
|
|
Gastrointestinal haemorrhage
|
|
|
|
|
subjects affected / exposed
|
2 / 2144 (0.09%) |
2 / 2124 (0.09%) |
1 / 2125 (0.05%) |
2 / 2136 (0.09%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 2 |
0 / 1 |
1 / 2 |
deaths causally related to treatment / all
|
1 / 1 |
0 / 0 |
0 / 0 |
1 / 1 |
Small intestine obstruction
|
|
|
|
|
subjects affected / exposed
|
2 / 2144 (0.09%) |
1 / 2124 (0.05%) |
2 / 2125 (0.09%) |
2 / 2136 (0.09%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
0 / 2 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Abdonimal pain
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
2 / 2124 (0.09%) |
2 / 2125 (0.09%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
0 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Inguinal hernia
|
|
|
|
|
subjects affected / exposed
|
2 / 2144 (0.09%) |
1 / 2124 (0.05%) |
1 / 2125 (0.05%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Colitis
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
2 / 2124 (0.09%) |
1 / 2125 (0.05%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Pancreatitis acute
|
|
|
|
|
subjects affected / exposed
|
2 / 2144 (0.09%) |
1 / 2124 (0.05%) |
1 / 2125 (0.05%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Constipation
|
|
|
|
|
subjects affected / exposed
|
2 / 2144 (0.09%) |
0 / 2124 (0.00%) |
1 / 2125 (0.05%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Enteritis
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
1 / 2125 (0.05%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Upper gastrointestinal haemorrhage
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
2 / 2124 (0.09%) |
0 / 2125 (0.00%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Abdominal hernia
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Colitis ulcerative
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Diverticular perforation
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
1 / 2125 (0.05%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Duodenal ulcenrn
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Gastrooesophageal reflux disease
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Ileus
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
2 / 2124 (0.09%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Large intestine polyp
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
1 / 2125 (0.05%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Anal fissure
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Colitis microscopic
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
1 / 2125 (0.05%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Diverticulum
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Diverticulum intestinal haemorrhagic
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
1 / 2125 (0.05%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Duodenal perforation
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Duodenal ulcer haemorrhage
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Dysphagia
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Enterocolitis
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
1 / 2125 (0.05%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Gastric ulcer
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Gastric ulcer perforation
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Gastritis
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Haemoroidal haemorrhage
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
1 / 2125 (0.05%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Haemorrhoids thrombosed
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Impaired gastric emptying
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Intestinal Infarction
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Intestinal obstruction
|
|
|
|
|
subjects affected / exposed
|
2 / 2144 (0.09%) |
0 / 2124 (0.00%) |
1 / 2125 (0.05%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
1 / 2 |
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Intestinal polyp
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Mesenteric artery stenosis
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Obstructive pancreatitis
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Pharyngo-oesophageal diverticulum
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Retroperitoneal haemorrhage
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Toothache
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Varices oesophageal
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Vomiting
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Diaphragmatic hernia
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Erosive oesophagitis
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
1 / 2125 (0.05%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Large intestinal haemorrhage
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Hepatobiliary disorders
|
|
|
|
|
Cholecystitis acute
|
|
|
|
|
subjects affected / exposed
|
2 / 2144 (0.09%) |
2 / 2124 (0.09%) |
3 / 2125 (0.14%) |
3 / 2136 (0.14%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 2 |
0 / 3 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Cholelithiasis
|
|
|
|
|
subjects affected / exposed
|
3 / 2144 (0.14%) |
0 / 2124 (0.00%) |
4 / 2125 (0.19%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 0 |
0 / 4 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Cholecystitis
|
|
|
|
|
subjects affected / exposed
|
2 / 2144 (0.09%) |
0 / 2124 (0.00%) |
1 / 2125 (0.05%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Hepatic cirrohsis
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Bile duct obstruction
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
1 / 2125 (0.05%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Cholangitis
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Cholecystitis Chronic
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Hepatic failure
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Hepatic function abnormal
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
1 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Hepatitis toxic
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Skin and subcutaneous tissue disorders
|
|
|
|
|
Skin lesion
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Swelling face
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Urticaria
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Renal and urinary disorders
|
|
|
|
|
Nephrolithiasis
|
|
|
|
|
subjects affected / exposed
|
2 / 2144 (0.09%) |
1 / 2124 (0.05%) |
3 / 2125 (0.14%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
0 / 3 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Renal failure
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
2 / 2124 (0.09%) |
0 / 2125 (0.00%) |
2 / 2136 (0.09%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Acute kidney injury
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
2 / 2124 (0.09%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Urinary retention
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
0 / 2124 (0.00%) |
1 / 2125 (0.05%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
1 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Renal colic
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
2 / 2124 (0.09%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Anuria
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
1 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Chronic kidney disease
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
1 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Haemorrhage urinary tract
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Hydronephrosis
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Lower urinary tract symptoms
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Ureterolithiasis
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Urinary bladder haemorrhage
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Glomerulonephritis chronic
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Endocrine disorders
|
|
|
|
|
Adrenal mass
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Goitre
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Musculoskeletal and connective tissue disorders
|
|
|
|
|
Osteorthritis
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
2 / 2124 (0.09%) |
3 / 2125 (0.14%) |
3 / 2136 (0.14%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
0 / 3 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Back pain
|
|
|
|
|
subjects affected / exposed
|
2 / 2144 (0.09%) |
1 / 2124 (0.05%) |
2 / 2125 (0.09%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
0 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Intervertebral disc protrusion
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
0 / 2124 (0.00%) |
2 / 2125 (0.09%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 2 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Osteonecrosis
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
1 / 2124 (0.05%) |
1 / 2125 (0.05%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Rotator cuff syndrome
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
4 / 2125 (0.19%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 4 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Lumbar spinal stenosis
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Arthralgia
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
1 / 2125 (0.05%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Flank pain
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
1 / 2125 (0.05%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Bursitis
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Costochondritis
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Groin pain
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Intervertebral disc degeneration
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Muscular weakness
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
1 / 2125 (0.05%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Pain in extremity
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Rhabdomyolysis
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
1 / 2125 (0.05%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Spinal ligament
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Spinal osteoarthritis
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Spondylolisthesis
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Synovial cyst
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Synovitis
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Cervical spinal stenosis
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
2 / 2124 (0.09%) |
0 / 2125 (0.00%) |
2 / 2136 (0.09%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Musculoskeletal pain
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Infections and infestations
|
|
|
|
|
Pneumonia
|
|
|
|
|
subjects affected / exposed
|
61 / 2144 (2.85%) |
59 / 2124 (2.78%) |
35 / 2125 (1.65%) |
55 / 2136 (2.57%) |
occurrences causally related to treatment / all
|
8 / 63 |
3 / 64 |
3 / 37 |
4 / 57 |
deaths causally related to treatment / all
|
1 / 1 |
1 / 1 |
2 / 2 |
1 / 1 |
Sepsis
|
|
|
|
|
subjects affected / exposed
|
7 / 2144 (0.33%) |
5 / 2124 (0.24%) |
5 / 2125 (0.24%) |
3 / 2136 (0.14%) |
occurrences causally related to treatment / all
|
0 / 8 |
0 / 5 |
0 / 5 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
2 / 2 |
Cellulitis
|
|
|
|
|
subjects affected / exposed
|
4 / 2144 (0.19%) |
6 / 2124 (0.28%) |
4 / 2125 (0.19%) |
3 / 2136 (0.14%) |
occurrences causally related to treatment / all
|
0 / 4 |
0 / 6 |
0 / 4 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Influenza
|
|
|
|
|
subjects affected / exposed
|
4 / 2144 (0.19%) |
2 / 2124 (0.09%) |
2 / 2125 (0.09%) |
7 / 2136 (0.33%) |
occurrences causally related to treatment / all
|
0 / 4 |
0 / 2 |
0 / 2 |
0 / 7 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Diverticulitis
|
|
|
|
|
subjects affected / exposed
|
3 / 2144 (0.14%) |
3 / 2124 (0.14%) |
3 / 2125 (0.14%) |
4 / 2136 (0.19%) |
occurrences causally related to treatment / all
|
0 / 4 |
0 / 3 |
0 / 3 |
0 / 5 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Bronchitis
|
|
|
|
|
subjects affected / exposed
|
2 / 2144 (0.09%) |
3 / 2124 (0.14%) |
4 / 2125 (0.19%) |
3 / 2136 (0.14%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 3 |
0 / 4 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Urinary tract infection
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
4 / 2124 (0.19%) |
2 / 2125 (0.09%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 4 |
0 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Respiratory tract infection
|
|
|
|
|
subjects affected / exposed
|
2 / 2144 (0.09%) |
2 / 2124 (0.09%) |
0 / 2125 (0.00%) |
2 / 2136 (0.09%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 2 |
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Lung infection
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
2 / 2124 (0.09%) |
1 / 2125 (0.05%) |
2 / 2136 (0.09%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
0 / 1 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Lower respiratory tract infection
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
2 / 2124 (0.09%) |
2 / 2125 (0.09%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
0 / 2 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Appendicitis
|
|
|
|
|
subjects affected / exposed
|
2 / 2144 (0.09%) |
0 / 2124 (0.00%) |
2 / 2125 (0.09%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Septic shock
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
1 / 2124 (0.05%) |
1 / 2125 (0.05%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
1 / 1 |
0 / 0 |
0 / 0 |
1 / 1 |
Erysipelas
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
2 / 2125 (0.09%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Pneumonia bacterial
|
|
|
|
|
subjects affected / exposed
|
3 / 2144 (0.14%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Pneumonia viral
|
|
|
|
|
subjects affected / exposed
|
2 / 2144 (0.09%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Staphylococcal infection
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
3 / 2125 (0.14%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 3 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Wound infection
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
2 / 2136 (0.09%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Anal abscess
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
2 / 2125 (0.09%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Device related infection
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
2 / 2124 (0.09%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Gastroenteritis
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
1 / 2125 (0.05%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Peritonitis
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
0 / 2124 (0.00%) |
1 / 2125 (0.05%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Pneumonia pneumococcal
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Pulmonary tuberculosis
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Respiratory syncytial virus infection
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Urosepsis
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
1 / 2125 (0.05%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Arthritis bacterial
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Bacterial pyelonephritis
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Bronchitis viral
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
1 / 2125 (0.05%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Bronchopulmonary aspergillosis
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Bronchopulmonary aspergillosis allergic
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Bursitis infective
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Campylobacter infection
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Catheter site cellulitits
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
1 / 2125 (0.05%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Cellulitis of male external genital organ
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Cholecystitis infective
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
1 / 2125 (0.05%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Clostridium difficile colitis
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
1 / 2125 (0.05%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Colonic abscess
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Emphysematous cholecystitis
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Encephalitis brain stem
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Endocarditis
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Epididymitis
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
1 / 2125 (0.05%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Gastroenteritis norovirus
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Gastroenteritis salmonella
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Gastroenteritis shigella
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
1 / 2125 (0.05%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Gastroenteritis viral
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
H1N1 influenza
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
1 / 2125 (0.05%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
1 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Histoplasmosis
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Infected bite
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Infected dermal cyst
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
1 / 2125 (0.05%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Infective exacerbation of bronshiectasis
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
1 / 2125 (0.05%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Laryngitis
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
1 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Localised infection
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
1 / 2125 (0.05%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Mastitis
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Mastoiditis
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Micrococcus infection
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Oesophageal candidiasis
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Osteomyelitis
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Otosalpingitis
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Perichondritis
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Periorbital cellulitis
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Pneumonia pseudomonal
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Post procedural sepsis
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Pyelonephritis
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Respiratory tract infection viral
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Sinusitis
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Soft tissue infection
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
1 / 2125 (0.05%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Tracheobronchitis
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Vaginal infection
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
1 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Viral infection
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Metapneumovirus infection
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Pneumonia streptococcal
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Metabolism and nutrition disorders
|
|
|
|
|
Fluid overload
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
2 / 2124 (0.09%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Hyperglycaemia
|
|
|
|
|
subjects affected / exposed
|
2 / 2144 (0.09%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Hypoglycaemia
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Hyponatremia
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Abnormal loss of weight
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Dehydration
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Diabetes melitus
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
1 / 2125 (0.05%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Diabetes melitus inadequate control
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Hyperlipidemia
|
|
|
|
|
subjects affected / exposed
|
1 / 2144 (0.05%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Impaired fasting glucose
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Metabolic acidosis
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Obesity
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
1 / 2124 (0.05%) |
0 / 2125 (0.00%) |
0 / 2136 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Vitamin B12 deficiency
|
|
|
|
|
subjects affected / exposed
|
0 / 2144 (0.00%) |
0 / 2124 (0.00%) |
0 / 2125 (0.00%) |
1 / 2136 (0.05%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |